A new lab-made compound slowed brain tumor growth in cells and fish
Original title: Discovery of iodo-phenanthroimidazole derivatives as potential HDAC1 inhibitors inducing mitophagy to suppress glioblastoma progression.
How far along is this research?
- Lab cells
- Animals
- Review
- Tested in people
This was done on cells in a lab, not in people. It is a very early step.
This was only done on cells in a dish and on fish.
The short version
This is very early lab work, not a treatment people can get.
What was studied. Scientists built new compounds in the lab and tested them on a protein called HDAC1. They tried the compounds on human glioblastoma: The fastest-growing type of glioma (grade 4). Treatment usually starts soon after diagnosis: surgery first, then radiation and chemotherapy. See the glossary cells in a dish and on zebrafish with brain tumors.
What they found. One compound, called compound 3, latched onto HDAC1 and blocked it. It slowed the growth of glioblastoma: The fastest-growing type of glioma (grade 4). Treatment usually starts soon after diagnosis: surgery first, then radiation and chemotherapy. See the glossary cells in the dish and damaged the parts of the cells that make energy. In zebrafish, it reached the brain and slowed tumor growth and spread.
What this means, and what it doesn't
What it could mean: Researchers have a new compound worth studying. It offers a fresh idea for how to go after glioblastoma: The fastest-growing type of glioma (grade 4). Treatment usually starts soon after diagnosis: surgery first, then radiation and chemotherapy. See the glossary. That idea now has to be tested much further.
What it doesn't mean: This does not mean a new treatment is coming soon. The work was done on cells in a dish and on fish, not on people. No one knows yet if it is safe or if it helps humans at all. Many years of testing would come first. This is not a cure.
Source: PubMed, August 12, 2026 · Read the original
This plain-language summary was written by AI and published automatically after passing our automatic safety checks. How we write.